BUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug

Reuters01-28

** Shares of drug developer CalciMedica CALC.O fall 84% to 84 cents premarket

** Co says an independent committee flagged safety concerns in the mid‑stage trial of Auxora for severe kidney injury, which could impact the organ's functioning

** Committee asked the co to review how patients were being enrolled

** No deaths were linked to the drug and no serious side effects required urgent FDA reporting, per co

** Co says it will review the data to decide if Auxora can be tested again; all enrolled patients will complete follow‑up

** Auxora had previously been tested in pancreatitis and COVID‑19 pneumonia without major safety issues, per co

** Shares up ~86% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606971120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606971120","market":"nz","top_or_hot":-1,"title":"BUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug</title></head><body><p>** Shares of drug developer CalciMedica <span>CALC.O</span> fall 84% to 84 cents premarket</p><p>** Co says an independent committee flagged safety concerns in the mid‑stage trial of Auxora for severe kidney injury, which could impact the organ's functioning</p><p>** Committee asked the co to review how patients were being enrolled</p><p>** No deaths were linked to the drug and no serious side effects required urgent FDA reporting, per co</p><p>** Co says it will review the data to decide if Auxora can be tested again; all enrolled patients will complete follow‑up</p><p>** Auxora had previously been tested in pancreatitis and COVID‑19 pneumonia without major safety issues, per co</p><p>** Shares up ~86% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-28 21:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug</title></head><body><p>** Shares of drug developer CalciMedica <span>CALC.O</span> fall 84% to 84 cents premarket</p><p>** Co says an independent committee flagged safety concerns in the mid‑stage trial of Auxora for severe kidney injury, which could impact the organ's functioning</p><p>** Committee asked the co to review how patients were being enrolled</p><p>** No deaths were linked to the drug and no serious side effects required urgent FDA reporting, per co</p><p>** Co says it will review the data to decide if Auxora can be tested again; all enrolled patients will complete follow‑up</p><p>** Auxora had previously been tested in pancreatitis and COVID‑19 pneumonia without major safety issues, per co</p><p>** Shares up ~86% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CALC","symbol_name":"CALCIMEDICA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL4N3YT1IY:1","article_id":"2606971120","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606971120","pubTimestamp":1769606953,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug** Shares of drug developer CalciMedica CALC.O fall 84% to 84 cents premarket** Co says an independent committee flagged safety concerns in the midstage trial of Auxora for severe kidney injury, which could impact the organ's functioning** Committee asked the co to review how patients were being enrolled** No deaths were linked to the drug and no serious side effects required urgent FDA reporting, per co** Co says it will review the data to decide if Auxora can be tested again; all enrolled patients will complete followup** Auxora had previously been tested in pancreatitis and COVID19 pneumonia without major safety issues, per co** Shares up ~86% in 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CALC":"CALCIMEDICA","BK4007":"制药"},"translate_title":"BUZZ-CalciMedica因安全问题停止肾损伤药物试验而股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":0.9},"content_text":"BUZZ-CalciMedica tumbles as safety concerns halt trial of kidney injury drug** Shares of drug developer CalciMedica CALC.O fall 84% to 84 cents premarket** Co says an independent committee flagged safety concerns in the mid‑stage trial of Auxora for severe kidney injury, which could impact the organ's functioning** Committee asked the co to review how patients were being enrolled** No deaths were linked to the drug and no serious side effects required urgent FDA reporting, per co** Co says it will review the data to decide if Auxora can be tested again; all enrolled patients will complete follow‑up** Auxora had previously been tested in pancreatitis and COVID‑19 pneumonia without major safety issues, per co** Shares up ~86% in 2025(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606971120","isCrawlerRequest":true}